Table 1 Claims-based algorithm for accessing effectiveness after one year of follow-up in patients with rheumatoid arthritis
From: Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study
Criteria | Description of criteria |
|---|---|
Criterion 1 High adherence | Adherence to therapy was defined as follows: • For medications with pharmacy claims only: MPR ≥ 80%a • For medications with procedure claims only: Etanercept: ≥ 48 procedures Adalimumab: ≥ 22 procedures Certolizumab: ≥ 22 procedures Golimumab: ≥ 11 procedures Infliximab: ≥ 8 procedures Rituximab: ≥ 4 procedures Abatacept: ≥ 11 procedures Tocilizumab: ≥ 11 procedures |
Criterion 2 No prescription or procedure of a new biologic or tofacitinib during follow-up | No prescription or procedure of a new biologic or tofacitinib during follow-up |
Criterion 3 No DMARD switch or addition | No prescription of a new DMARD between months 4 and 12 of follow-up |
Criterion 4 No increase in dose or frequency of index drug | No increase in dose or frequency of index drug • For medications with pharmacy claims only: ≥ 10% of the daily dose at any time during follow-up compared with the daily dose at cohort entry • For medications with procedure claims only: Adalimumab: > 25 procedures Certolizumab: > 25 procedures Golimumab: > 12 procedures Infliximab: > 9 procedures Rituximab: > 5 procedures Abatacept: > 13 procedures Tocilizumab: > 12 procedures Etanercept: > 55 procedures |
Criterion 5 No more than one procedure for glucocorticoid joint injection between months 4 and 12 of follow-up | No more than one procedure for glucocorticoid joint injection between months 4 and 12 of follow-up |
Criterion 6 No new/increased oral glucocorticoid dose | No increase in dose of oral glucocorticoid • For patients who received no prescriptions for oral glucocorticoids 6 months prior to cohort entry: > 30 days of cumulative oral glucocorticoid between months 4 and 12 of follow-up • For patients who received prescriptions for oral glucocorticoids 6 months prior to cohort entry: cumulative dose between months 7 and 12 of follow-up ≥ 120% cumulative dose 6 months prior to cohort entry |